Slide 1: Driving the Next Generation of Cell-Based Therapies
are trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT August 2026 © 2026 MaxCyte, Inc. All Rights Reserved
Slide 2: Forward Looking Statement Disclaimer
Forward Looking Statement Disclaimer 2 © 2026 MaxCyte, Inc. All Rights Reserved Certain statements in this document (this “Presentation”) are, or may be deemed to be, forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995
Slide 3: MaxCyte at a Glance
MaxCyte at a Glance 3 © 2026 MaxCyte, Inc. All Rights Reserved Our Mission We power the future of cell and gene therapy with innovative, scalable cell engineering solutions that enable our customers to deliver advanced therapies to patients Base-editing (CRISPR), CRISPR, ARCUS, RNA-Based Engineering
Slide 4: Cell and Gene Therapy Development
Cell and Gene Therapy Development 4 © 2026 MaxCyte, Inc. All Rights Reserved Cell Engineering (Electroporation) Cell Proliferation In-Vivo Ex-Vivo Viral/Non-Viral Vector for delivery to Specific Organ Tissue The engineering of cells to develop therapies addressing a host of human diseases with unmet
Slide 5: Addressing the Challenges of Cell & Gene Therapy Development
Addressing the Challenges of Cell & Gene Therapy Development 5 © 2026 MaxCyte, Inc. All Rights Reserved Next-generation cell therapy programs have become increasingly complex requiring multiple edits Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) Vein
Slide 6: Large Opportunity in Ex-Vivo Cell and Gene Therapy
Large Opportunity in Ex-Vivo Cell and Gene Therapy 6 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte # of Potential SPLs Research & Discovery Pre-Clinical Clinical Commercial 124 Programs 82 Non-Viral Programs (66%) 383 Programs 193 Non-Viral Programs (50%) 249 Programs 84 Non-Viral Programs (34%)
Slide 7: The Expert Platform Enabling Non-Viral Cell Engineering
The Expert Platform Enabling Non-Viral Cell Engineering 7 © 2026 MaxCyte, Inc. All Rights Reserved Full scale RUO Small/mid-scale RUO Large Scale RUO/cGMP Full scale RUO/cGMP 75 thousand to 700 million cells 75 thousand to 20 billion cells 5 billion to 200 billion cells 75 thousand to 20 billion cel
Slide 8: MaxCyte's Solutions Span Cell & Gene Engineering
Instrument purchase & research scale GMP: 25µL – 100mL on GTx 21 CFR Part 11 Compliant MaxCyte’s Solutions Span Cell & Gene Engineering 8 © 2026 MaxCyte, Inc. All Rights Reserved Industry-leading, scalable Expert Electroporation Platform and best-in-class customer support Commercial Strategic platfo
Slide 9: Flow Electroporation integrates within a closed cGMP cell therapy workflow
MaxCyte’s Flow Electroporation® technology integrates efficiently within a closed cGMP cell therapy workflow 9 © 2026 MaxCyte, Inc. All Rights Reserved Cell Isolation & Expansion CCBE Electroporation Cell Expansion Cryopreservation Add loading agent (mRNA, pDNA, RNP…) and Electroporate Process cells
Slide 10: Development of Ex Vivo Cell Therapies Requires Highly Specialized Engineering Tools and Assays
Development of Ex Vivo Cell Therapies Requires Highly Specialized Engineering Tools and Assays 10 © 2026 MaxCyte, Inc. All Rights Reserved Lentivirus Adeno-associated virus Lipid nanoparticles Electroporation Engineering Tools Delivery Technologies CRISPR/Cas gene editing Transposase integration mRN
Slide 11: MaxCyte's Solutions are Uniquely Positioned to Support Cell Therapy Development
MaxCyte’s Solutions are Uniquely Positioned to Support Cell Therapy Development 11 © 2026 MaxCyte, Inc. All Rights Reserved Flow Electroporation technology facilitates multiplex and sequential engineering without the payload and capacity limitations of viral approaches 23+1 Field Application Scienti
Slide 12: Platform Generates Recurring Revenue in Pre-Clinical, Clinical, and Commercial
MaxCyte’s Platform Generates Recurring Revenue in Pre-Clinical, Clinical, and Commercial 12 © 2026 MaxCyte, Inc. All Rights Reserved Razor/Razor Blade Economics Full scale RUO Preclinical and Academic Revenue Model Instrument Sale Clinical and Commercial Revenue Model Annual License Fee Razor/Razor
Slide 13: MaxCyte has an Active Portfolio of SPLs
Lyell Immunopharma MaxCyte has an Active Portfolio of SPLs 13 © 2026 MaxCyte, Inc. All Rights Reserved 29 SPL Partners1 Sana Biotechnology Beam Therapeutics cGMP Compatible Platform FDA Master File and Technical Files Experienced FAS and sales support Leading know-how and engineering process improve
Slide 14: Typical MaxCyte SPL Economics
Typical MaxCyte SPL Economics 14 © 2026 MaxCyte, Inc. All Rights Reserved Early Clinical: (Phase 1/2) Years 1-3 • Mid 6-figure up to low 7-figure milestones • 1-3+ instruments + disposables Mid-late Clinical: (Phase 2/3) Years 3-5+ • 7-figure milestone • Increasing instrument and disposables usage A
Slide 15: Differentiated Commercial Relationships Expand Sales Funnel
Differentiated Commercial Relationships Expand Sales Funnel 15 © 2026 MaxCyte, Inc. All Rights Reserved Highly Technical Employees Field Application Scientists (FAS) and Commercial Team Unparalleled scientific support to customers Customer relationships at early stages of cell & gene therapy develop
Slide 16: SPL Portfolio: 14 Active Clinical Trials
16 © 2026 MaxCyte, Inc. All Rights Reserved As of June 2026 / Includes with SPL Programs with multiple Clinical Trials for different indications SPL Portfolio: 14 Active Clinical Trials Partner Program Phase Cell Approach Cell Type Disease Area Vertex Pharmaceuticals CASGEVY Commercial Autologous HS
Slide 17: SPL Case Study: CASGEVY
SPL Case Study: CASGEVY® 17 © 2026 MaxCyte, Inc. All Rights Reserved CASGEVY® for Sickle Cell Disease (SCD) and for Transfusion-Dependent Beta-Thalassemia (TDT) (2023 and 2024) 2013 – MaxCyte supports Inception Genomics (Changed name to CRISPR Therapeutics AG in 2014) • Support for programs in resea
Slide 18: MaxCyte Supports the Future of Cell & Gene Therapies
MaxCyte Supports the Future of Cell & Gene Therapies 18 © 2026 MaxCyte, Inc. All Rights Reserved WAVE 1 1 Approved Product WAVE 2 5 Product Candidates WAVE 3 7 Product Candidates WAVE 4 17 Product Candidates Vertex/ CRISPR CASGEVY® Approved 2023 US FDA, European Commission & Additional Regulatory Bo
Slide 19: Genentech Partnership
Genentech Partnership Multi-Platform Technology License Partnership An enterprise-level relationship providing Genentech access to MaxCyte's ExPERT GTx® platform and additional platform technologies across research, clinical development, and commercial manufacturing workflows Enterprise Framework St
Slide 20: An Expanding Partnering Model for Large Pharma
An Expanding Partnering Model for Large Pharma Enterprise partnerships complement MaxCyte's Strategic Platform License (SPL) model Strategic Platform License (SPL) Product-by-product Non-exclusive license to ExPERTTM platform for biotechs developing individual therapeutic programs An attractive solu
Slide 21: Roadmap to Becoming a Premier Cell Engineering Solutions Provider
MaxCyte’s Roadmap to Becoming a Premier Cell Engineering Solutions Providers 21 © 2026 MaxCyte, Inc. All Rights Reserved Electroporation technology provider Comprehensive cell engineering solutions Gene Editing Tools Over $1.25b market • Key markets addressed: in vivo and ex vivo cell therapy • Othe
Slide 22: Editing Assessment Services Strategy
Editing Assessment Services Strategy 22 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte provides ex-vivo and in-vivo developers with best-in-class on-target and off-target risk assessment services Use Cases: candidate guide screening, guide RNA selection Use Cases: Off-target risk assessment, guide
Slide 23: Financial Summary
23 © 2026 MaxCyte, Inc. All Rights Reserved Financial Summary $2.1 $1.8 $3.1 $2.3 $2.6 $1.8 $0.1 $0.3 $0.3 $0.3 2Q25 2Q26 Core Revenue: (21%) Decline $7.1 $6.8 $14.0 $11.9 $10.3 $8.9 $1.1 $1.2 $6.1 $3.4 2024 2025 Core Revenue: (9%) Decline 1. Excluding SPL Program-related revenue and reserves for ex
Slide 24: Financial Summary
Financial Summary 24 © 2026 MaxCyte, Inc. All Rights Reserved In millions, except percentages 2024 2025 YTD 2026 Total Core Revenue $32.5 $29.6 $12.7 y/y growth 9% (9%) (23%) SPL-Program Related Revenue $6.1 $3.4 $4.2 y/y growth (47%) (44%) 71% Total Revenue $38.6 $33.0 $16.9 y/y growth (6%) (15%) (
Slide 25: Disciplined Management is Committed to Growth Investment and Efficient Spending
Disciplined Management is Committed to Growth Investment and Efficient Spending 25 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte is well capitalized and funded to achieve profitability with existing capital Alignment of spending and resources to growth areas Organic investment in new products and
Slide 26: Thank you! Any questions?
All other trademarks are the property of their respective owners. ©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit maxcyte.com/trademarks. Thank you! Any questions? ir@maxcyte.com 26 © 2026 MaxCyte, Inc. All Rig
Slide 27: Appendix – Historical Core Business Disclosure
Appendix – Historical Core Business Disclosure 27 © 2026 MaxCyte, Inc. All Rights Reserved 2Q'22 3Q'22 4Q'22 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q’24 3Q’24 4Q’24 1Q’25 2Q’25 3Q’25 4Q’25 1Q’26 2Q’26 (in $ thousands) Instrument 2,697 2,575 3,705 2,189 2,126 1,672 2,330 1,928 1,762 1,764 1,629 1,444 2,141 1
Slide 28: Appendix – Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin
Appendix – Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin 28 © 2026 MaxCyte, Inc. All Rights Reserved 1. Adjustments include the exclusion of SPL program related revenue from Revenue, and the exclusion of reserves for excess and obsolete inventory from Cost of Goods Sold.
Slide 29: Appendix – Unaudited Reconciliation of Net Loss to Adjusted EBITDA
Appendix – Unaudited Reconciliation of Net Loss to Adjusted EBITDA 29 © 2026 MaxCyte, Inc. All Rights Reserved Unaudited Reconciliation of Net Loss to Adjusted EBITDA (in thousands) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net loss $ (8,874) $ (12,357) $